Evidence map›Paper›PMID 41031823›Full record

ReviewClinical microbiology reviews2025

Twenty years of human bocavirus research: from an unculturable virus of unclear pathogenicity to a culturable human pathogen and gene therapy vector candidate.

Oliver Schildgen, Jianming Qiu, Mario Mietzsch, Tobias Allander, Tuomas Jartti, Verena Schildgen, Dirk Grimm, Maria Söderlund-Venermo

Abstract readReview
In one paragraph

Review in Clinical microbiology reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Oliver SchildgenKliniken der Stadt Köln gGmbH, Institut für Pathologie, Klinikum der Privaten Universität Witten/Herdecke, Cologne, Germany.ORCID 0000-0003-4297-9627
Jianming QiuDepartment of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, Kansas, USA.ORCID 0000-0001-9850-1695
Mario MietzschDepartment of Biochemistry and Molecular Biology, College of Medicine, Center for Structural Biology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.
Tobias AllanderDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Tuomas JarttiDepartment of Pediatrics and Adolescent Medicine, University of Turku and Turku University Hospital, Turku, Finland.
Verena SchildgenKliniken der Stadt Köln gGmbH, Institut für Pathologie, Klinikum der Privaten Universität Witten/Herdecke, Cologne, Germany.
Dirk GrimmSection Viral Vector Technologies, Department of Infectious Diseases/Virology, Medical Faculty and Faculty of Engineering Sciences, BioQuant, Heidelberg University, German Center for Infection Research (DZIF), German Center for Cardiovascular Research (DZHK), Heidelberg, Germany.
Maria Söderlund-VenermoDepartment of Virology, University of Helsinki, Helsinki, Finland.

Funding

Structural studies of AAV capsids and their glycan receptor interactionsR01GM082946 · NIGMS · UNIVERSITY OF FLORIDA · PI ROBERT MCKENNA · 2007 to 2026
$6.1M
Viral and Host Determinants of Parvovirus ReplicationR01AI150877 · NIAID · UNIVERSITY OF KANSAS MEDICAL CENTER · PI QIU, JIANMING · 2020 to 2024
$2.4M
Development of novel approaches for gene editing therapies of cystic fibrosisR01HL174593 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Jianming Qiu, Ziying Yan · 2024 to 2026
$1.9M
Development of myotropic human bocavirus vectors for gene therapyR21AI182645 · NIAID · UNIVERSITY OF KANSAS MEDICAL CENTER · PI QIU, JIANMING, YAN, ZIYING · 2024 to 2025
$441k
Beatrix-Lichtken-StiftungLife and Heatlh Medical AssociationLörcher-StiftungNational Institute of Allergy and Infectious Diseases AI150877,AI182645NHLBI NIH HHS HL174593NHLBI NIH HHS R01 HL174593NIAID NIH HHS R01 AI150877NIAID NIH HHS R21 AI182645NIGMS NIH HHS GM082946NIGMS NIH HHS R01 GM082946Sigrid Juséliuksen Säätiö
6 · The paper itself

Abstract

SUMMARYTwenty years after the first description of human bocavirus 1 (HBoV1) as a respiratory pathogen, significant progress has been made in both clinical and basic research; however, important clinical, diagnostic, and molecular challenges remain before bocavirus pathobiology is fully understood. The discovery of HBoV1 and its notorious prolonged shedding have challenged the new sensitive multiplex PCR panel-based diagnostic testing that replaced the old antigen assays, leading to erroneous classification of HBoV1 as an innocent bystander. Both sophisticated diagnostics and cytopathic effects in cell culture have now confirmed HBoV1 to be a common cause of upper and lower respiratory tract infections, mainly in children. While many questions have been answered, new questions have emerged as our understanding of parvoviruses has significantly expanded over the past two decades. In this review, key findings from 20 years of clinical, basic, and applied research on human bocaviruses are summarized and open questions highlighted to guide future investigations.

Indexed as

Human bocavirusParvoviridae InfectionsRespiratory Tract InfectionsAnimalsGenetic TherapyGenetic VectorsHumans20 yearsHBoVhuman bocavirusrespiratory tract

Identifiers

PMID41031823
PMCPMC12697176

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.